Deadline for manuscript submissions: 31 July 2023Print Special Issue Flyer (4)
Department of Obstetrics and Gynecology, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
Interests: Gynecologic Oncology; Gynaecological Surgery; Endometriosis; Hysterectomy
Medical Oncologist; Cabrini, Peninsula and Melbourne Health Services, VIC, Australia. Adjunct Associate Professor, Monash University, VIC, Australia
Interests: Medical Oncology; Hereditary Cancer Syndromes; Breast Cancer; Gynaecological Cancers; Endometrial Cancer
Endometrial cancer is the most common of gynecological cancers affecting women in developed countries with rates also fast rising in developing nations. The increasing incidence of endometrial cancer relate to both an aging population but also to the increasing rates of obesity- one of the well-recognized risks for endometrial cancer. In addition, hereditary conditions including Lynch and Cowden’s Syndrome also contribute to endometrial cancer risk. There are four molecularly distinct subtypes of endometrial cancer using the TCGA classification model- each with their own prognostic implications and therefore impacts on treatment decisions. While most patients are managed with surgery, with a high likelihood of cure, there are women with endometrial cancer for whom surgical decisions remain difficult- in particular around fertility preservation, lymph node assessment and surgical benefit in those with extensive nodal involvement, or in those where co-existent significant obesity adds to surgical risks. Similarly adjuvant treatment guidelines exist, but with increasing complexity in who could be managed without adjuvant therapy and what therapies are effective in reducing risk of recurrence. In the setting of advanced endometrial cancer, combination platinum based therapy remains the gold standard for first line systemic therapy- but the recent expansion of understanding of the benefit of immune therapy (single agent or in combination) will this current standard be challenged- particularly in those with mismatch repair deficient tumors where responses to immune checkpoint inhibitors are more likely. The use of endocrine therapy remains mixed despite a large proportion of tumors expressing estrogen receptors. The overall prognosis for women with advanced disease remains very poor and therefore the scope for expanded therapeutics is high.
The aim of this special edition is to focus on the management of endometrial cancer with the aim of improving outcomes for women with both early and advanced endometrial cancer.
Nicolae Gica, MD, PhD and Yoland Antill, BMed FRACP MD
Endometrial Cancer; High-risk Factors; Adjuvant Treatment; Endocrine Therapy; Targeted Therapy
Manuscripts should be submitted online by submit system. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Original articles, case reports or comprehensive reviews are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website. Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. European Journal of Gynaecological Oncology is an international peer-reviewed open access journal published by MRE Press. Please visit the Instructions for Authors page before submitting a manuscript.The Article Processing Charge (APC) for publication in this open access journal is $1200. We normally offer a discount greater than 30% to all contributors invited by the Editor-in-Chief, Guest Editor (GE) and Editorial board member. Submitted papers should be well formatted and use good English.
Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.
Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.
Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.
JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.
Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.
BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.
Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.